Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MDM4 | O15151 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.56 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.55 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.51 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9845322 | 0.84 | HDAC1 (0.60) | KMT2ASMN1; SMN2MEN1POLBKCNQ3 | |
| SCHEMBL3787980 | 0.84 | MDM4 (0.70) | KMT2ARAB9ASMN1; SMN2MEN1NPC1 | |
| SCHEMBL9845318 | 0.81 | LCK (0.57) | KMT2A | |
| SCHEMBL4059827 | 0.81 | KMT2A (0.60) | KMT2ARAB9ASMN1; SMN2MEN1NPC1 | |
| SCHEMBL3782440 | 0.81 | RAB9A (0.58) | KMT2ARAB9ASMN1; SMN2MEN1NPC1 | |
| SCHEMBL9845394 | 0.81 | HCAR3 (0.55) | KMT2ASMN1; SMN2MEN1POLBALDH1A1 | |
| SCHEMBL1275562 | 0.80 | RAB9A (0.53) | KMT2ARAB9ASMN1; SMN2MEN1NPC1 | |
| SCHEMBL9845375 | 0.79 | RXFP1 (0.48) | KMT2ASMN1; SMN2MEN1POLBCYP1A2 | |
| SCHEMBL14652150 | 0.79 | LCK (0.55) | — | |
| SCHEMBL11123393 | 0.79 | RXFP1 (0.59) | KMT2ARAB9ASMN1; SMN2MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1028945-B9 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1028945-B1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-6458813-B1 | 2-CYCLOHEXYLOXY-5-(2-CHLOROPHENYLCARBONYLAMINO)PYRIDINE, FOR EXAMPLE; TREATING INFLAMMATION, PAIN, DIABETES, CANCER | AMGEN INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020035094-A1 | Substituted pyridine compounds and methods of use | AMGEN INC. | 2002-03-21 | — | — | US | disclosed |
| US-6333341-B1 | TUMOR NECROSIS FACTOR, ANTIINFLAMMATORY AGENTS AND ANALGESICS | AMGEN INC. | 2001-12-25 | — | — | US | disclosed |
| US-6184237-B1 | Substituted pyridine compounds and methods of use | AMGEN INC. | 2001-02-06 | — | — | US | disclosed |
| EP-1028945-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | Amgen Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| US-6022884-A | PROPHYLAXIS OR TREATMENT OF INFLAMMATION | AMGEN INC. (US) | 2000-02-08 | — | — | US | disclosed |
| WO-1999024404-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC. (US) | 1999-05-20 | — | — | WO | disclosed |
| EP-0405931-A2 | Improvements in and relating to anticonvulsant agents | ELI LILLY AND COMPANY (US) | 1991-01-02 | — | — | EP | disclosed |
| US-4973597-A | PYRIDINECARBOXAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1990-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035094-A1 | Substituted pyridine compounds and methods of use | IL1B, IL6, IL1A | KMT2A 3820/4885RAB9A 2767/4885SMN1; SMN2 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.